OTCPicks.com

FEATURED COMPANY

LANTIS LASER INCORPORATED (OTC: LLSR)

Detailed Quote: http://www.otcpicks.com/quotes/LLSR.php

Company Profile: http://www.otcpicks.com/lantis-laser/lantis-laser-2.htm

Lantis Laser was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System™ in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); LightLab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser, visit www.lantislaser.com.

LLSR News:

July 2 - Independent Research Shows More Uses for Lantis Laser's OCT Technology

Lantis Laser Inc. (OTC: LLSR) (www.lantislaser.com), is drawing attention to the increasing applications of Optical Coherence Tomography (OCT).

In a recently published study in Journal of Endodontics (June 2008) by Shemesh H et al at the Academic Center for Dentistry in Amsterdam, Holland, showing OCT application in root canal therapy for detecting root fractures before filling the canal, it was concluded that OCT is a promising method for non-destructive imaging of the root surfaces. Earlier published research by the same group, showed that OCT could detect perforations and other possible defects that could affect a successful outcome of root canal therapy. Dentists have never been able to obtain this information by any other means.

Lantis Laser has exclusive worldwide rights for OCT technology in the $5 Billion dental equipment industry. The technology, which was developed at MIT, is the next generation in medical imaging following the X-ray, ultrasound, and MRI.

Stan Baron, President & CEO of Lantis, commented that, "The more applications OCT can be used for, the more dentists would find it indispensable and this would, of course, accelerate the rate of adoption of Dental OCT and the market penetration."

Lantis is initially targeting its Dental OCT System for use in the early detection of tooth decay, secondary decay under and around fillings, root surface decay and decay under sealants. However many other applications are surfacing that would indicate that Lantis OCT Dental Imaging System would be deployed in a dental office for many more applications than originally envisaged.

Application in orthodontics have been indicated relating to the detection of early demineralization, the precursor to decay, using OCT. Orthodontic treatment requires patient compliance to achieve optimum levels of oral hygiene, particularly around brackets. OCT can detect early demineralization, a sign that the patient may need special attention to ensure that "white spots" on teeth do not detract from successful treatment. A recent publication by Cosmin Sinescu et al in Int. Soc. Opt Eng. ( May 2008) shoed research to using OCT to examined the outcome of different bracket bonding materials and procedures that could affect stability of bracket retention and minimize failures.

Lantis' OCT Dental Imaging System enables the dentist to do diagnostic imaging, chairside and in real-time. As the power source is light-based, unlike x-ray there is no harmful radiation. Images can be captured at a resolution of to 10 times that of x-ray, enabling early detection of decay and detailed examination of microstructural defects.

FEATURED COMPANY

CARBON SCIENCES INCORPORATED (OTCBB: CABN)

Detailed Quote: www.otcpicks.com/quotes/CABN.php

Company Profile:
www.otcpicks.com/carbon-sciences/carbon-sciences-2.htm

Carbon Sciences, Inc. focuses on developing GreenCarbon technology to convert carbon dioxide into a form that would not contribute to global warming. Its GreenCarbon technology is targeted at coal-fired electrical power plants and fuel production plants. The company was founded in 2006 as Zingerang, Inc. and changed its name to Carbon Sciences, Inc. in April 2007. Carbon Sciences, Inc. is based in Santa Barbara, California.

CABN News:

July 1 - RedChip Visibility Issues First Quarter 2008 Research Update On Carbon Sciences, Inc.

RedChip Visibility, a division of RedChip Companies, Inc. announced it has issued a first quarter 2008 research update on Carbon Sciences, Inc. (OTCBB: CABN), a company engaged in developing its GreenCarbon™ Technology which converts harmful carbon dioxide into useful carbon products.

Neha Bhargava, MBA, RedChip Research Analyst, reported:

“CABN has recently announced the first application of its breakthrough technology whereby it plans to convert CO2 into Precipitated Calcium Carbonate (PCC), a valuable chemical compound that can be used in the manufacturing of paper, paint, pharmaceutical products, rubber, adhesives, and plastics. GreenCarbon PCC is cost effective, as it uses inexpensive raw material and can be used as a standalone or satellite plant to existing PCC operations of target customers.

“We believe CABN stock will gain as the Company's new business strategy focusing on the PCC market will enable it to report revenues earlier than our previous estimates. Growing demand for PCC products and the demand-supply gap are the positive catalysts for CABN stock,” Bhargava continued.

“CABN's plan to produce PCC to position itself in the CO2 mitigation market, which is estimated to reach $400 billion by 2030, confirms our positive viewpoint of CABN's technology. Even the political scenario that has undergone a radical change supporting CO2 mitigation regulations favors CABN. We reiterate our 'Speculative Buy' rating on CABN and are revising our 12-month target price to $0.85,” she concluded.

To receive a complimentary copy of the RedChip Visibility 1Q08 Research Report for CABN, visit www.redchip.com/visibility/about.asp?page=vreport&reportid=120&from=07012008pr.

FEATURED COMPANY

WIND ENERGY AMERICA INCORPORATED (OTCBB: WNEA)

Detailed Quote: www.otcpicks.com/quotes/WNEA.php

Company Profile:
www.otcpicks.com/wind-energy-america/wind-energy-america-2.htm

Wind Energy America Inc. develops and operates wind energy projects in the Great Plains and the Midwest, regions known for their high quality wind energy resources. The Company owns interests in three wind farms: Shaokatan Hills LLC, Lakota Ridge LLC and CHI Energy. At present, WNEA owns a developer's stake and a minimal interest producing negligible cash flow in these wind farms. Over the next two years the developer’s stake will begin producing significant cash flow from these projects. The three wind farms together contain 79 modern wind turbines and have a total rated capacity of 53.5 megawatts (MW). They are collectively generating approximately 160 million kilowatt hours (kWh) of electricity annually. In addition to these properties, the Company owns a 3 percent equity interest in Averill Wind LLC, a 10 MW wind farm being developed near Fargo, N.D., another region favorable for wind power energy.

WNEA News:

July 1 - Howard Lapidus Joins Board of Wind Energy America, Inc.

Wind Energy America Inc. (OTCBB: WNEA) announced that it has added Howard Lapidus to its Board of Directors. Mr. Lapidus brings a unique business perspective to WNEA through his large and small company entrepreneurial business experience.

As a veteran of the seafood industry for 21 years, Mr. Lapidus has worked for both Pillsbury and Cargill in managerial positions and in smaller food industry companies. In his past business career, he worked for one of the largest multinational food groups in Indonesia and became their national sales manager. After working for a $500 million privately-held Food Company in Los Angeles, as the Executive Vice President, he started his own seafood import company, HL Seafood, Inc., located in Chaska, MN.

Mr. Lapidus lives with his wife and three children in Chaska, MN and is a graduate of the University of Minnesota.

CEO of Wind Energy America, Darrel Kluge, commented, “Wind Energy America is in the process of adding quality Board members to enhance its opportunities. Howard is a tremendous asset to the Board of Directors. As an investor in Wind Energy himself, Howard’s intuitive understanding of wind industry dynamics and business acumen can present creative solutions that leverage the high growth opportunities for Wind Energy America Inc.”

In connection to his appointment, Mr. Lapidus stated, “For some time, I have seen a tremendous opportunity developing within the wind energy industry. With the costs of fossil fuels skyrocketing, Wind Energy America can play an active role in the mitigation of our country’s use of these traditional fuels. Our company’s recent acquisitions bring both significant value and revenue to the company from electrical energy sales.”

FEATURED COMPANY

XSUNX INCORPORATED (OTCBB: XSNX)

Detailed Quote: http://www.otcpicks.com/quotes/XSNX.php

Company Profile: http://www.otcpicks.com/xsunx/xsunx.htm

Xsunx, Inc., a thin-film photovoltaic (TFPV) company, focuses on developing thin film photovoltaic (TFPV) amorphous silicon solar cell manufacturing processes to produce TFPV solar modules. Its product includes XsunX ASI-120 module, which is a 125 peak watt TFPV solar module utilizing glass substrates and a proprietary semiconductor manufacturing system. XsunX ASI-120 provides for a module delivering high power output, and size and framing that would allow for the use of various existing mounting systems. The target markets for the TFPV solar module include solar farms, government agencies, and utility companies, as well as power purchase agreements and large commercial installations worldwide. The company, formerly known as Sun River Mining, Inc., was incorporated in 1997 and changed its name to XsunX, Inc. in 2003. XsunX is headquartered in Aliso Viejo, California.

XSNX News:

July 1 - Research Update Issued on XsunX, Target Price $1.50 Reiterated by Beacon Equity Research

XsunX Inc. (OTCBB: XSNX) has been rated a “Speculative Buy” with a reiterated price target of $1.50 by Beacon Equity Research Analyst, Victor Sula, Ph.D.

The full report is available at www.beaconequity.com/adpages/XSNX.

In the report, the analyst writes, “With reserved capacity already approaching 145 MW, lower manufacturing costs per watt that will drive a rapid adoption of the TFPV modules and recent progress toward establishing commercial production, we believe XSNX remains on track to report meaningful revenues by year-end 2008 and achieve our $60 million revenue target in 2009.”

FEATURED COMPANY

MONOGRAM ENERGY INCORPORATED (OTC: MGRN)

Detailed Quote: www.otcpicks.com/quotes/MGRN.php

Company Profile:
www.otcpicks.com/monogram-energy/monogram-energy.htm

Monogram Energy, Inc. is an independent energy company engaged in the acquisition, development, and exploitation of oil and gas properties. The company specializes in acquiring oil & gas leases with proven reserves that have the potential for increased production.

MGRN News:

June 30 - Monogram Energy, Inc. Continues Workover Program

Monogram Energy, Inc. (OTC: MGRN), an independent energy company engaged in the acquisition, development, and exploitation of oil and gas properties, announced that it will begin the workover of two wells on the T.W. Martin lease in Navarro County, Texas today. The T.W. Martin lease comprises 70 acres with 12 wells, of which 6 are currently producing. The 6 wells are expected to produce 2 barrels per well, per day. This represents a 50% increase in projected production stated in the Monogram Energy press release on May 13, 2008, increasing production from 270 barrels per month to 540 barrels per month.

With oil prices skyrocketing to an all time high of $140 per barrel in June, Monogram could realize revenues of over $400,000.00 USD over the next six months.

Preliminary estimates show that the wells to be worked over will increase production by 28% per well. If the Company realizes this increase in production, it will approve the workover of the additional wells that are in production.

Mr. Billy King, Chief Executive Officer of Monogram Energy, Inc., stated, "We are very pleased with the progress being made with the Company. This workover program on the T.W. Martin lease will yield dramatic revenue growth. We are striving for all of the wells on the T.W. Martin lease to be functioning at full capacity by the end of the year."

Mr. King became interested in the production of oil & gas during his ten years of employment as an attorney for the Halliburton Company, and with his representation of independent oil companies during his years as a private practitioner. Monogram Energy's goal is to maintain a high risk/reward profile, thereby enabling them to return the most value to its shareholders.

STOCKS TO WATCH

E*TRADE FINANCIAL CORPORATION (NASDAQ: ETFC)
"Up 5.02% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ETFC.php

E*TRADE Financial Corporation, through its subsidiaries, offers financial solutions to retail and institutional customers worldwide. It provides retail investments and trading, which include automated order placement and execution of equities, currencies, futures, options, exchange-traded funds, mutual funds, and bonds, as well as offers quick transfer, wireless account access, extended hours trading, quotes, and research and advanced planning tools. The company also offers various banking and financial services that include checking, savings, sweep, and money market accounts; certificates of deposit products; mortgage, home equity, margin, and credit card products; and various loans, including one to four-family, home equity, recreational vehicle, marine, commercial, automobile, and credit card loans. In addition, it provides advisory and asset management services to retail clients. E*TRADE Financial primarily provides services through its Web site at www.etrade.com, as well as through its network of customer service representatives, relationship managers, and investment advisors. The company was founded in 1982 and is based in New York, New York.

ETFC News:

July 1 - Joseph Sclafani Joins E*TRADE FINANCIAL Board of Directors

E*TRADE Financial Corporation (NASDAQ: ETFC) announced that Joseph L. Sclafani, retired executive vice president and controller, J.P. Morgan Chase & Co., has joined the Board of Directors of E*TRADE Financial Corporation effective June 30, 2008. Mr. Sclafani, 59, will be a member of the Company’s Finance and Risk Oversight Committee and the Company’s Audit Committee, where he will be designated a financial expert.

“Joe is one of the most experienced corporate controllers in the industry, and his knowledge of accounting and financial issues is second-to-none,” said Donald H. Layton, Chairman of the Board and Chief Executive Officer for E*TRADE Financial Corporation. “His knowledge and experience will be of tremendous value to us as we rebuild E*TRADE’s financial health and return to growth.”

“E*TRADE's legacy as a strong franchise with a powerful brand is indisputable," said Mr. Sclafani. "I look forward to contributing my industry experience and perspective to assist in executing the straightforward and solid plan the management team has in place to achieve long-term growth.”

Mr. Sclafani’s 38 years of experience include 27 years at J.P. Morgan Chase & Co. and its predecessors, serving most recently as Corporate Controller responsible for corporate financial operations, regulatory reporting, financial accounting and reporting and accounting policies. Mr. Sclafani also spent 11 years at KPMG as a certified public accountant.

Mr. Sclafani earned a BA from St. Francis College in Brooklyn and completed post-graduate studies in finance at Bernard Baruch.

ABOUT E*TRADE FINANCIAL

The E*TRADE Financial family of companies provides financial services including trading, investing and banking for retail and institutional customers. Securities products and services are offered by E*TRADE Securities LLC (Member FINRA/SIPC). Bank products and services are offered by E*TRADE Bank, a Federal savings bank, Member FDIC, or its subsidiaries.

HEARTLAND OIL & GAS CORPORATION (OTCBB: HTOG)
"Up 41.98% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/HTOG.php

Heartland Oil and Gas Corp. engages in exploration, development, production, and sale of coal bed methane in the Cherokee basin and Forest City basin of northeast Kansas. The company owns and operates oil and gas leases located on approximately 645,000 acres of property in the Forest City and Cherokee basins in eastern Kansas; 700 acres of property in Palo Pinto County, Texas; and 3,000 acres in Jack County, Texas. It also holds properties in Kansas in the south block, located on the Cherokee basin; and the north block, located in the Forest City basin. In addition, the company engages in the processing and sale of gas through pipelines from its Lancaster wells. As of December 31, 2007, Heartland Oil and Gas had proved developed net reserves of 2,410,484 thousand cubic feet of gas; and 3,002 thousand barrels of crude oil. The company was founded in 1998 and is based in Houston, Texas. Heartland Oil & Gas Corp. operates as a subsidiary of Universal Property Development and Acquisition Corporation.

HTOG News:

July 2 - Heartland Completes and Successfully Pressure Tests 4 Mile Pipeline, Installation of Flow Lines to Commence for Connection of 12 Wells Expected to Double Coalbed Methane Production

Heartland Oil and Gas Corp. (OTCBB: HTOG) (FWB: HOCA) has successfully conducted pressure testing on its new 4 mile pipeline in Kansas, signaling the completion of that pipeline. Work was then immediately commenced to install the flow lines to each of the 12 new wells to be connected in order to begin the sale of the coalbed methane being generated by those wells.

With this successful testing and anticipated connection of 12 wells, Heartland expects to double the coalbed methane production from this field in Southeast Kansas. In addition, vast additional acreage will be open for further development and drilling along the 4 miles to be accessed by the pipeline.

“We put the necessary pressure into the pipeline and found no leaks along its entire length,” reports Augie Soto, COO of Aztec Well Services, Heartland’s prime contractor on the work. “The four road crossings and 2 creek crossings were our greatest concern and they held without any problems. The 8 inch main is tied into the 12 inch main and the pipeline is secure all the way to the sales meter. We will begin installation of the 4 inch flow lines without delay and have scheduled the contractor to fracture the wells so they are ready for production as soon as we can connect them.”

MAXYGEN INCORPORATED (NASDAQ: MAXY)
"Up 34.19% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/MAXY.php

Maxygen, Inc., a biotechnology company, engages in the discovery, development, and commercialization of protein pharmaceuticals for treatment of disease and serious medical conditions in the United States. The company's product candidates comprises MAXY-G34, a granulocyte colony stimulating factor that is in Phase IIa clinical trial for the treatment of neutropenia; MAXY-VII, a factor VIIa product that is in pre-clinical stage for the treatment of hemophilia and acute bleeding conditions; and MAXY-4, a CTLA-4-Ig product for the treatment of rheumatoid arthritis and other immune or autoimmune diseases. It has a strategic alliance with Roche Holdings, Ltd. for the development and commercialization of Maxygen's portfolio of next-generation interferon alpha and beta variants for a range of indications. The company was founded in 1996 and is headquartered in Redwood City, California.

MAXY News:

July 1 - Bayer HealthCare and Maxygen Announce Hematology Agreement

*Portfolio of hemophilia drug candidates includes novel recombinant Factor VIIa
*$120 million transaction includes license to Maxygen's novel biotechnology research platform
*Phase 1 clinical testing expected to commence in third quarter

Bayer HealthCare is expanding its commitment to hemophilia with the acquisition of Maxygen’s (NASDAQ: MAXY) hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. The lead therapeutic candidate is expected to enter Phase 1 clinical testing in the third quarter of 2008. The total transaction is valued at $90 million upfront with a final, potential milestone payment of $30 million. This agreement includes a license to use Maxygen’s MolecularBreeding™ technology, a novel research platform, for exploiting gene targets.

Hemophilia is an inherited bleeding disorder caused by deficient or defective blood coagulation proteins. Roughly 20 to 30 percent of patients with hemophilia develop antibodies – or inhibitors – to current therapies. In these instances a Factor VIIa is used to bypass inhibitors and help these individuals to form clots. MAXY-VII is a next generation Factor VIIa clotting factor that may offer an improved dosing regimen and safety profile. The addition of a development candidate for patients with clotting factor inhibitors could further build Bayer’s leadership position in hemophilia care where it offers the recombinant Factor VIII product, Kogenate® (antihemophilic factor [recombinant]). The company has a strong development program dedicated to hemophilia including ongoing clinical investigations into long-acting forms of Kogenate.

“MAXY-VII has the potential to be an important expansion of therapeutic options for people living with hemophilia and we are pleased to add this to our global development portfolio. The agreement fits into our growth strategy for our specialty pharmaceutical business and builds on our expertise in the commercialization and manufacturing of protein therapeutics,” said Dr. Gunnar Riemann, member of the Executive Committee of Bayer HealthCare. “Our scientists are actively collaborating with researchers in academia and biotechnology firms to leverage novel research platforms. Access to Maxygen’s MolecularBreeding™ technology provides us with another tool to expand our product pipeline.”

“This agreement allows Maxygen to capture significant value from this preclinical asset, and puts MAXY-VII in the hands of the hemophilia leader,” said Russell Howard, chief executive officer of Maxygen. “MAXY-VII has the potential to become the world’s first approved shuffled protein therapeutic, a milestone that is likely to open up many more opportunities for Maxygen’s technology. Bayer is the ideal company to move the MAXY-VII program toward that goal.”

Bayer also receives a non-exclusive license to use Maxygen’s MolecularBreeding™ technology for a broad set of genes for its internal use in its specialty pharmaceutical business. In addition, Bayer receives exclusive rights to use the technology for 30 specified gene targets in areas of strategic business interest. This novel platform allows scientists to exploit gene variation that can result in unique drug targets or novel therapeutic protein candidates.

ABOUT MAXY-VII AND HEMOPHILIA

MAXY-VII is designed to be an improved Factor VIIa for the treatment of hemophilia patients. Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints or internal organs. The disease is caused by deficient or defective blood coagulation proteins, known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX. According to the World Federation of Hemophilia, about 1 in 10,000 people is born with hemophilia A and 1 in 50,000 people is born with hemophilia B. Over time, roughly 20 to 30 percent of patients develop antibodies to these replacement factors (frequently referred to as inhibitors).

ABOUT THE MOLECULARBREEDING™ DIRECTED EVOLUTION PLATFORM

MolecularBreeding™, also known as gene shuffling, is an iterative process of recombination and selection. The products of these recombined genes (proteins) are then screened for the targeted drug properties. This novel platform allows scientists to exploit gene variation that can result in unique drug targets or novel therapeutic protein candidates.

ABOUT KOGENATE® FS/KOGENATE® BAYER

Kogenate® FS (Antihemophilic Factor [Recombinant]) / KOGENATE® Bayer (Recombinant Coagulation Factor VIII [octocog alfa]) is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The safety, efficacy and overall reliability of the Kogenate® line of products are based on 20 years of clinical experience. Clinical data shows that Kogenate® provided excellent hemostatic control, was well tolerated, and has a proven safety profile in patients with hemophilia A. Kogenate® is manufactured at Bayer’s state-of-the-art biotechnology facility in Berkeley, California. The most frequently reported adverse events were local injection site reactions, dizziness and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate®. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate®.

ABOUT BAYER HEALTHCARE

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at www.bayerscheringpharma.de.

UNIVERSAL ENERGY CORPORATION (OTCBB: UVSE)
"Up 26.67% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/UVSE.php

Universal Energy Corp., an independent energy company, engages in the acquisition and development of crude oil and natural gas leases in the United States and Canada. As of December 31, 2007, it had working interest in approximately 7,095 acres of land in Louisiana and Texas, as well as in Alberta, Canada. The company, formerly Universal Tanning Ventures, Inc., was founded in 2002 and is based in Lake Mary, Florida.

UVSE News:

July 1 - Universal Energy Corp. Begins Installation of Intermediate Casing at its Lone Oak Prospect in Galveston Bay, Texas

Universal Energy Corp. (OTCBB: UVSE), announced that drilling at its Lone Oak Prospect in Galveston Bay, Texas has reached a measured depth of 11,586 feet. Logging of the hole was completed yesterday and installation of 7 5/8 inch intermediate casing will now be installed to a depth of 11,470 feet. It is estimated that drilling operations at Lone Oak will be completed by July 12, 2008.

Billy Raley, Chief Executive Officer of Universal Energy Corp. stated "We are very excited with the progress at Lone Oak so far. It is important for oil and gas exploration and production companies throughout the United States to continue exploration within our borders." Raley continued, "Building reserves for U.S. consumers, and U.S. stockholders, should be the rallying cry for every E&P company operating within the United States."

Universal Energy Corp. is a publicly-traded energy company engaged in the acquisition and development of crude oil and natural gas leases in the United States. We pursue oil and gas prospects in partnership with oil and gas companies with exploration, development and production expertise. Our prospect areas consist of lands in Louisiana and Texas. Visit www.universalenergycorp.info for more details.

FRANKLIN MINING INCORPORATED (OTC: FMNJ)
"Up 54.55% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/FMNJ.php

Franklin Mining, Inc. primarily has mining and energy interests in the United States and Bolivia. It also holds various energy interests for the development and construction of gas-to-liquid facilities in Argentina. Franklin Mining, Inc. was formerly known was WCM Capital, Inc. The company was founded in 1864 and is headquartered in San Antonio, Texas with additional offices in La Paz and Santa Cruz, Bolivia and Buenos Aires, Argentina.

FMNJ News:

July 1 - Franklin Appointed to Represent Capital Oil & Gas, Ltd. in South America

Prepared to Deliver Diesel in Argentina and Paraguay

Franklin Mining, Inc.'s (OTC: FMNJ) (Frankfurt: FMJ.F) Chairman and President, William A. Petty, announces that Franklin was named a representative of Capital Oil & Gas, Ltd. (London) in April 2008 and authorized to negotiate the purchase of crude and refined petroleum products in the countries of Bolivia, Argentina and Colombia. "With Capital Oil & Gas' success in Europe, Africa and Asia, I am excited to be their representative as they prepare to enter South American markets," he said when releasing his June 30, 2008 Memorandum to be posted on the company web-site. "Franklin Oil & Gas, Argentina SA entered negotiations almost immediately following Capital Oil & Gas' April 8, 2008 appointment."

Mr. Petty also stated that, in addition to negotiating Capital Oil & Gas purchases, Franklin Oil & Gas, Argentina SA has entered negotiations with Energia Argentina Sociedad Anonima (ENARSA) for the delivery of up to 200,000 MT per month of diesel fuel and with Paraguayan Petroleum (Petróleos Paraguayos, PETROPAR) for the delivery of up to 250,000 MT per month. ENARSA is Argentina's national oil company; PETROPAR is Paraguay's national oil company.

LATITUDE INDUSTRIES INCORPORATED (OTC: LTDI)
"Up 20.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/LTDI.php

Latitude Industries is a manufacturer of high-quality, offshore sport fishing boats. The company's boats fuse innovative design with advanced lightweight composite materials that resist rot and decay and retain buoyancy under all conditions. Hand-laid fiberglass hulls offer the best of old world craftsmanship and new world technology. In addition, the company enhances the safety of its boats by using the latest lamination technology, creating a sturdy and durable hull that can handle the toughest sea conditions. Latitude Industries employs craftsmen with decades of industry experience at its headquarters in South Florida, the sport fishing capital of the world. For more information about Latitude Industries Inc. visit www.latitudepowerboats.com.

LTDI News:

July 2 - Latitude Industries, Inc. Issues Shareholder Update

Latitude Industries, Inc. (OTC: LTDI), a manufacturer of high-performance, center console powerboats, would like to update current and prospective shareholders due to excessive phone calls, e-mails, and speculations in regards to the share structure.

Latitude Powerboats' latest share structure has remained as follows: 1,979,767,839 shares outstanding with 1,347,408,357 shares free trading and 632,359,482 shares restricted.

"In the following week we will be updating and clarifying our shareholders in regards to Honda and the possible Buy Out status," said Orlando Hernandez, CEO of Latitude Powerboats.

PURESPECTRUM INCORPORATED (OTC: PSPM)
"Up 20.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/PSPM.php

PureSpectrum is a publicly traded technology company founded and headquartered in Savannah, Ga. The company's values are grounded in an awareness of the increasing urgency to identify more efficient energy solutions. PureSpectrum currently holds the rights to multiple patents and patent applications related to an electronic ballast design which would produce a soft switching environment during power conversion for artificial lighting. PureSpectrum will continue its commitment to researching, developing and refining ideas that will provide the most energy efficient, cost effective methods for powering artificial light. For more information on PureSpectrum, call (912) 961-4980 or visit www.purespectrumlighting.com.

PSPM News:

July 2 - PureSpectrum, Inc. Continues Patenting Process for Multiple Technologies

Lighting Technology Company Moving Toward Three Additional Patents Pending This Month

PureSpectrum, Inc. (OTC: PSPM) will further solidify its intellectual property portfolio by filing patent applications for three provisional patents to be upgraded to patent applications by the end of July.

PureSpectrum, which owns several patents and patents pending related to electronic ballast technology, plans to file applications with the U.S. Patent and Trademark Office for patent application status for dimmable ballast technology for Compact Fluorescent Light (CFL) bulbs, a dimmable ballast design for linear fluorescent bulbs and a two-wire dimming device for CFL bulbs.

According to lighting industry experts, dimming is a critical issue for fluorescent lighting as the country prepares for the legislated extinction of incandescent bulbs in 2012. PureSpectrum president and CEO Lee Vanatta said protecting his company's dimming technology through the patenting process is essential because PureSpectrum is the only lighting technology company to engineer a ballast circuitry design that enables CFL bulbs to dim without interruption like incandescent bulbs have dimmed for decades.

"Our goal from the outset has been to engineer our technology to be compatible with the production process for lighting manufacturers, and we are now in the process of patenting technologies which have been refined with input received from major lighting manufacturers," said PureSpectrum president and CEO Lee Vanatta. "Rather than operating blindfolded, we intentionally addressed our technologies to issues within the lighting industry, and we've been rewarded with open lines of communication and positive feedback from major manufacturers. The continuation of the patenting process is simply an extension of the vision that produced the corporate strategy we have followed during the development process."

The company is engaged in ongoing discussions with several prospective licensing partners in the lighting industry, and multiple lighting manufacturers have conducted private performance tests on the dimming technology during the past three months. PureSpectrum recently commissioned additional independent testing at the request of potential licensees, and the company continues to refine the technologies based on feedback gleaned from interactions with lighting manufacturers.

Call (912) 961-4980 for more information about PureSpectrum, Inc. or visit www.purespectrumlighting.com to see a short video featuring PureSpectrum's dimming technology compared to commercially available dimmable CFL bulbs. Please contact Shareholder Development Group at (770) 518-3449 or This email address is being protected from spam bots, you need Javascript enabled to view it for investment information.